Dr. Serber's addition comes as ArkeaBio gears up for product validation and commercial rollout. On August 28, 2025, ArkeaBio, a global leader in agricultural bioscience focused on developing the first vaccine to mitigate methane emissions from cattle, announced Dr. Zach Serber’s appointment as Chief Technology Officer. With over 20 years of experience in the fields of synthetic biology and industrial biotechnology, Dr. Serber is recognized for transforming advanced scientific concepts into practical applications within the bioeconomy.

Previously, Dr. Serber served as the founder and Chief Science Officer at Zymergen, where he played a pivotal role in scaling the company from a startup to an IPO with nearly 1,000 employees. He directed the scientific strategy, integrated robotics and machine learning into industrial fermentation processes, and secured significant government and commercial contracts, including serving as Principal Investigator on multiple DARPA projects. His earlier work at Amyris included developing a yeast-based antimalarial drug, backed by the Gates Foundation, and advancing large-scale biofuel production in Brazil. Most recently, he held the position of Chief Operating Officer at Evozyne, an AI-focused protein engineering firm dedicated to developing novel enzymes and biologics for human and planetary health.

“Reducing methane emissions from livestock will have a more immediate and profound impact on climate change than electrifying the entire transportation sector,” said Dr. Serber. “Methane is over 80 times more potent than CO₂ in the short term, but it also breaks down faster, meaning reductions today can cool the planet within years, not decades. What excites me about this work is the scale of impact, the speed at which we can achieve it, and the potential to improve both climate outcomes and productivity on the farm, all at a fraction of the cost of most other climate solutions.”

As Chief Technology Officer, Dr. Serber will lead the scientific strategy while the team builds on the success of its discovery platform, pushing towards product validation and commercial deployment. ArkeaBio is on course to move its current animal studies into full field trials by 2026, with plans for a commercial launch shortly thereafter, aligning with 2030 emissions targets set by major corporations and governments.

“Zach brings new technical depth and leadership experience to accelerate and scale a world-class vaccine platform,” said Carmichael Roberts of Breakthrough Energy Ventures. “His appointment strengthens ArkeaBio’s ability to provide substantial new revenue opportunities for farmers and ranchers via agricultural carbon credits, unlocking a multibillion-dollar market in livestock methane reduction.”

About ArkeaBio, the company is at the forefront of agricultural bioscience, pioneering the first methane-reducing vaccine for cattle. The mission is to supply farmers with practical, scalable tools to decrease emissions while feeding a growing global population. Supported by prominent climate and agriculture investors, ArkeaBio’s vaccine targets a $4 billion global market for ruminant methane reduction, with considerable potential access to agricultural carbon markets valued in the tens of billions.